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• I want to know the mechanism of the diseases ???
• Probably you will need a suitable model ???
• I need a specific therapy (ASAP) ???
• We will need a lot of money 
to achieve all of that !!!   
Personalized medicine
FSHD is an autosomal dominant inherited disorder
Third most common inherited neuromuscular condition (1:8000)
Disease onset is unusual before the age of 10
Muscles on the face are first affected, then the symptoms are 
progressive
There is no specific treatment.
Facioscapulohumeral Muscular Dystrophy (FSHD)
Deletion on chromosome 4 is an initial factor for FSHD
Is DUX4 a key player in the molecular mechanism?
Predictions !!!
4q35A locus is open and transcriptionally active in FSHD
Bickmore and van de Maarel; 1993
DUX4 and FSHD
FSHD cells express DUX4
Control              + DUX4 Control       DUX4
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DUX4 induces cell death DUX4 affects myogenesis
Bosnakovski et al.; PlosOne 2009
Bosnakovski et al.; EMBO J 2008
Bosnakovski et al.; Exp Neurol 2008
